Humanized Liver Mice Model Market is Projected to Account for Over US$ 22.8 Mn in Terms of Value By 2026 End- Persistence Market Research

Humanized Liver Mice Model Market is Projected to Account for Over US$ 22.8 Mn in Terms of Value By 2026 End- Persistence Market Research

PR Newswire

NEW YORK, November 29, 2018

NEW YORK, November 29, 2018 /PRNewswire/ --

uPA-SCID Mice Model Segment Expected to Hold High Revenue Share in the Global Humanized Liver Mice Model Market

A large number of humanized liver mice models are available, including uPA-SCID mice, FRG KO mice, and TK-NOG mice, among others. Factors such as increasing incidence of liver cirrhosis, technological advancement and development of new humanized liver mice models, increase in number of FDA approvals for liver-based disease treatment dugs have increased the number of research and development activities, which require these models. However, the high cost of mice models as well as high shipping cost, and availability of alternatives are factors expected to hinder the growth of the humanized liver mice model market during the forecast period. Furthermore, regulatory challenges including patenting of mice and other ethical issues including the use of 3Rs policy are also expected to restrain the growth of the humanized liver mice model market. The global humanized liver mice model market is projected to account for over US$ 22.8 Mn in terms of value by 2026 end, according to a latest research by PMR. The report on the global humanized liver mice model market further projects significant growth potential with average year-on-year growth rate of 4.6% through 2026.

     (Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg )

Albumin enhancer/promoter-driven urokinase-type plasminogen and activator/severe combined immunedeficient mice are known as the uPA-SCID mice. These mice suffer from a transgene-induced liver disease, and are transplanted with primary human hepatocytes immediately after birth. These mice were one of the first humanized liver mice model developed with high chimerism and are the most common type of humanized liver mice models available. The TK-NOG mice are designed to express a Herpes Simplex Virus-1 Thymidine Kinase (HSVtk) transgene that is primarily driven by the albumin enhancer/promoter in the liver of the mice. This induces liver-specific injury when treated with gancyclovir. Human liver cells are then introduced into the liver of the mouse to replace the liver cells that are destroyed. The other type of humanized liver mice model that is gaining popularity is the FRG KO mice. The FRG KO mice are developed by knocking out three genes including Fah-/-; Rag2-/-; and Il2rg-/-. These mice overcome some of the drawbacks of the uPA-SCID mice such a low breeding capacity and genotype reversion. These mice have a slightly better breeding capacity and cannot undergo genotype reversion allowing the human hepatocytes to be serially transplanted into other mice. These humanized liver mice models also show high chimerism like the uPA-SCID mice.

Request Sample Report @ https://www.persistencemarketresearch.com/samples/25417

PMR has segmented the global humanized liver mice model market based on model, application, end user and region. The humanized liver mice model by model is further sub-segmented into uPA-SCID Mice, FRG KO Mice, TK-NOG Mice, and other models. Based on end users, the humanized liver mice model market is segmented into pharmaceutical companies, biotechnology companies, CRO's and academic & research institutes. CRO's segment is expected to hold maximum share in the global humanized liver mice model market followed by academic &research institutes segment. Based on application, the humanized liver mice model market is segmented into pharmacokinetic studies, in-vivo liver toxicity testing, drug metabolism studies, and other applications.

Humanized Liver Mice Model Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/humanized-liver-mice-model-market.asp

North America is expected to be the dominant regional market for humanized liver mice model. This is due to the support for research activities by the government as well as private sectors. Government funding and support for patenting genetically modified mice are other factors that support the growth of the humanized liver mice model market in North America. China is also expected to be a lucrative regional market for humanized liver mice model due to the changing regulations of the government to support the pharmaceutical and biopharmaceutical industries in the region.

Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/methodology/25417

The report tracks some of the key companies operating in the humanized liver mice model market, including Yecuris Corporation, PhoenixBio Group, Beijing Vitalstar Biotechnology Co. Ltd., Hera BioLabs, Taconic Biosciences, Inc., University of Massachusetts Medical School, Oncodesign, University of Nebraska Medical Center and Jackson Laboratory.

More from PMR's Life Sciences & Transformational Health Market Intelligence:

Immune Checkpoint Inhibitors Market: segmented on the basis of drug class - PD-1, PD-L1, CTLA-4 ; On the basis of therapeutic application - Lung Cancer, Melanoma Squamous Cell Carcinoma, Urothelial Carcinoma, Blood cancer, Other Cancers ; On the basis of the distribution channel - Hospital Pharmacies, Retail Pharmacies: https://www.persistencemarketresearch.com/market-research/immune-checkpoint-inhibitors-market.asp  

Progressive Multifocal Leukoencephalopathy Treatment Market: Segmented Based on drug type anti-retroviral therapy, antiviral/anti JCV and other symptomatic;Based on indication HIV/AIDS, organ transplantation, multiple sclerosis and hematological malignancies;Based on distribution channel hospital pharmacies, drug stores and retail pharmacies: https://www.persistencemarketresearch.com/market-research/progressive-multifocal-leukoencephalopathy-treatment-market.asp  

Rna Based Therapeutics And Vaccines Market: segmented based on product type - RNA-based Therapeutics, RNA-based Vaccines (mRNA); On the basis of indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, genetic diseases & others: https://www.persistencemarketresearch.com/market-research/rna-based-therapeutics-and-vaccines-market.asp

Persistence Market Research Overview 

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

PMR Latest News: https://www.persistencemarketresearch.com/news


Voltar noticias em Inglês